The Inhibition of NS2B/NS3 Protease: A New Therapeutic Opportunity to Treat Dengue and Zika Virus Infection

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Apr 27

PMID 38673962

Authors

Jose Starvaggi

Santo Previti

Maria Zappala

Roberta Ettari

Affiliations

Soon will be listed here.

Abstract

In the global pandemic scenario, dengue and zika viruses (DENV and ZIKV, respectively), both mosquito-borne members of the flaviviridae family, represent a serious health problem, and considering the absence of specific antiviral drugs and available vaccines, there is a dire need to identify new targets to treat these types of viral infections. Within this drug discovery process, the protease NS2B/NS3 is considered the primary target for the development of novel anti-flavivirus drugs. The NS2B/NS3 is a serine protease that has a dual function both in the viral replication process and in the elusion of the innate immunity. To date, two main classes of NS2B/NS3 of DENV and ZIKV protease inhibitors have been discovered: those that bind to the orthosteric site and those that act at the allosteric site. Therefore, this perspective article aims to discuss the main features of the use of the most potent NS2B/NS3 inhibitors and their impact at the social level.

Citing Articles

TRIM38 Inhibits Zika Virus by Upregulating RIG-I/MDA5 Pathway and Promoting Ubiquitin-Mediated Degradation of Viral NS3 Protein.

He J, Kuang Y, Xu K, Huang R, Yang X, Deng L Viruses. 2025; 17(2).

PMID: 40006954 PMC: 11860351. DOI: 10.3390/v17020199.

Crystallographic fragment screening and deep mutational scanning of Zika virus NS2B-NS3 protease enable development of resistance-resilient inhibitors.

von Delft F, Ni X, Richardson R, Godoy A, Ferla M, Kikawa C Res Sq. 2025; .

PMID: 39989958 PMC: 11844641. DOI: 10.21203/rs.3.rs-5876218/v1.

Identifying Allosteric Small-Molecule Binding Sites of Inactive NS2B-NS3 Proteases of Pathogenic .

Grabski H, Grabska S, Abagyan R Viruses. 2025; 17(1).

PMID: 39861795 PMC: 11769402. DOI: 10.3390/v17010006.

Discovery of Potent Dengue Virus NS2B-NS3 Protease Inhibitors Among Glycyrrhizic Acid Conjugates with Amino Acids and Dipeptides Esters.

Lin Y, Lai H, Lin C, Hung P, Kan J, Chiu S Viruses. 2025; 16(12.

PMID: 39772233 PMC: 11680386. DOI: 10.3390/v16121926.

Identification and Evaluation of Natural Compounds as Potential Inhibitors of NS2B-NS3 Zika Virus Protease: A Computational Approach.

Anede N, Ouassaf M, Rengasamy K, Khan S, Alhatlani B Mol Biotechnol. 2024; .

PMID: 39733219 DOI: 10.1007/s12033-024-01357-6.

References

Poulsen A, Kang C, Keller T . Drug design for flavivirus proteases: what are we missing?. Curr Pharm Des. 2013; 20(21):3422-7. DOI: 10.2174/13816128113199990633. View

Li Q, Kang C . Insights into Structures and Dynamics of Flavivirus Proteases from NMR Studies. Int J Mol Sci. 2020; 21(7). PMC: 7177695. DOI: 10.3390/ijms21072527. View

Brecher M, Zhang J, Li H . The flavivirus protease as a target for drug discovery. Virol Sin. 2013; 28(6):326-36. PMC: 3927373. DOI: 10.1007/s12250-013-3390-x. View

Yin Z, Patel S, Wang W, Chan W, Rao K, Wang G . Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors. Bioorg Med Chem Lett. 2005; 16(1):40-3. DOI: 10.1016/j.bmcl.2005.09.049. View

Lennemann N, Coyne C . Dengue and Zika viruses subvert reticulophagy by NS2B3-mediated cleavage of FAM134B. Autophagy. 2017; 13(2):322-332. PMC: 5324851. DOI: 10.1080/15548627.2016.1265192. View

Chu J, Lee R, Ang M, Wang W, Lim H, Wee J . Antiviral activities of 15 dengue NS2B-NS3 protease inhibitors using a human cell-based viral quantification assay. Antiviral Res. 2015; 118:68-74. DOI: 10.1016/j.antiviral.2015.03.010. View

Bhagat R, Kaur G, Seth P . Molecular mechanisms of zika virus pathogenesis: An update. Indian J Med Res. 2022; 154(3):433-445. PMC: 9131805. DOI: 10.4103/ijmr.IJMR_169_20. View

Stoermer M, Chappell K, Liebscher S, Jensen C, Gan C, Gupta P . Potent cationic inhibitors of West Nile virus NS2B/NS3 protease with serum stability, cell permeability and antiviral activity. J Med Chem. 2008; 51(18):5714-21. DOI: 10.1021/jm800503y. View

Bastos Lima A, Behnam M, El Sherif Y, Nitsche C, Vechi S, Klein C . Dual inhibitors of the dengue and West Nile virus NS2B-NS3 proteases: Synthesis, biological evaluation and docking studies of novel peptide-hybrids. Bioorg Med Chem. 2015; 23(17):5748-55. DOI: 10.1016/j.bmc.2015.07.012. View

10.

Shiryaev S, Farhy C, Pinto A, Huang C, Simonetti N, Elong Ngono A . Characterization of the Zika virus two-component NS2B-NS3 protease and structure-assisted identification of allosteric small-molecule antagonists. Antiviral Res. 2017; 143:218-229. PMC: 5558795. DOI: 10.1016/j.antiviral.2017.04.015. View

11.

Sylte I, Dawadi R, Malla N, von Hofsten S, Nguyen T, Solli A . The selectivity of galardin and an azasugar-based hydroxamate compound for human matrix metalloproteases and bacterial metalloproteases. PLoS One. 2018; 13(8):e0200237. PMC: 6075749. DOI: 10.1371/journal.pone.0200237. View

12.

Chanprapaph S, Saparpakorn P, Sangma C, Niyomrattanakit P, Hannongbua S, Angsuthanasombat C . Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites. Biochem Biophys Res Commun. 2005; 330(4):1237-46. DOI: 10.1016/j.bbrc.2005.03.107. View

13.

Wahaab A, Mustafa B, Hameed M, Stevenson N, Anwar M, Liu K . Potential Role of Flavivirus NS2B-NS3 Proteases in Viral Pathogenesis and Anti-flavivirus Drug Discovery Employing Animal Cells and Models: A Review. Viruses. 2022; 14(1). PMC: 8781031. DOI: 10.3390/v14010044. View

14.

Lin K, Nalivaika E, Prachanronarong K, Yilmaz N, Schiffer C . Dengue Protease Substrate Recognition: Binding of the Prime Side. ACS Infect Dis. 2016; 2(10):734-743. PMC: 5221572. DOI: 10.1021/acsinfecdis.6b00131. View

15.

Nitsche C, Behnam M, Steuer C, Klein C . Retro peptide-hybrids as selective inhibitors of the Dengue virus NS2B-NS3 protease. Antiviral Res. 2012; 94(1):72-9. DOI: 10.1016/j.antiviral.2012.02.008. View

16.

Heaton N, Perera R, Berger K, Khadka S, LaCount D, Kuhn R . Dengue virus nonstructural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis. Proc Natl Acad Sci U S A. 2010; 107(40):17345-50. PMC: 2951450. DOI: 10.1073/pnas.1010811107. View

17.

Steuer C, Gege C, Fischl W, Heinonen K, Bartenschlager R, Klein C . Synthesis and biological evaluation of α-ketoamides as inhibitors of the Dengue virus protease with antiviral activity in cell-culture. Bioorg Med Chem. 2011; 19(13):4067-74. DOI: 10.1016/j.bmc.2011.05.015. View

18.

Weigel L, Nitsche C, Graf D, Bartenschlager R, Klein C . Phenylalanine and Phenylglycine Analogues as Arginine Mimetics in Dengue Protease Inhibitors. J Med Chem. 2015; 58(19):7719-33. DOI: 10.1021/acs.jmedchem.5b00612. View

19.

Behnam M, Nitsche C, Vechi S, Klein C . C-terminal residue optimization and fragment merging: discovery of a potent Peptide-hybrid inhibitor of dengue protease. ACS Med Chem Lett. 2014; 5(9):1037-42. PMC: 4160758. DOI: 10.1021/ml500245v. View

20.

Gangopadhyay A, Saha A . Exploring allosteric hits of the NS2B-NS3 protease of DENV2 by structure-guided screening. Comput Biol Chem. 2023; 104:107876. DOI: 10.1016/j.compbiolchem.2023.107876. View